What are blood clots?

Your browsing activity is empty. Activity recording is turned off. Turn recording back on. See more... Follow NCBI. Connect with NLM. National Library of ... Sep 19, 2021 ... Eculizumab is an anti-C5 humanized monoclonal antibody that binds to C5, preventing its cleavage into C5a and C5b. May 7, 2019 ... Treatment with eculizumab (Soliris, Alexion Pharmaceuticals) significantly reduces the risk for relapse among patients with AQP4-IgG ... Initially 900 mg once weekly for 4 weeks, then increased to 1.2 g once weekly for 1 week, followed by maintenance 1.2 g every 12–16 days, consider ... MEDICATION GUIDE. SOLIRIS® (so-leer-is). (eculizumab) injection, for intravenous use. What is the most important information I should know about SOLIRIS? NMOSD patients receiving Soliris should be monitored for early signs of meningococcal infection. No ongoing monitoring is recommended following discontinuation ... Jul 22, 2024 ... FDA Approves Epysqli as Second Soliris Biosimilar ... The FDA approves Samsung Bioepis' Epysqli (eculizumab-aagh), marking the second US approval ... ECULIZUMAB (ek yoo LYE zyoo mab) treats certain blood conditions that can cause low levels of red blood cells (anemia) and blood clots. SOLIRIS (eculizumab) is an FDA-approved prescription medicine used to treat adults with neuromyelitis optica spectrum disorder (NMOSD) Feb 7, 2024 ... Eculizumab is efficacious in acetylcholine receptor antibody (AChR-Ab)-positive refractory generalized myasthenia gravis (gMG).